About Remora Therapeutics
Remora Therapeutics is an early stage biotech company focused on developing a new class of platelet-based therapeutics. Platelets are best known for their role in blood clotting and wound healing, but are also known to selectively target diseased or damaged tissue and preferentially release their contents at these sites.
Founder: Lauren Adelaar
2 articles with Remora Therapeutics
On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
The company announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb’s 2017 Golden Tickets for LabCentral.